Interleukin 6 Signalling in Heart Failure With Preserved and Reduced Ejection Fraction

E V Samoilova1, A А Korotaeva1, I V Zhirov1

  • 1Chazov National Medical Research Center of Cardiology, Moscow.

Kardiologiia
|April 10, 2024
PubMed

Insights

Interleukin-6 (IL-6) signaling pathways differ between heart failure types. Understanding these inflammation pathways in chronic heart failure (CHF) may lead to new treatments.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) involves complex inflammatory processes.
  • Interleukin-6 (IL-6) plays a critical role in inflammation and cardiac remodeling.
  • IL-6 exerts its effects through distinct classical and trans-signaling pathways.

Purpose of the Study:

  • To identify and compare the IL-6 signaling pathways in patients with different types of CHF.
  • To investigate the differential expression of IL-6 and its receptors in acute decompensated heart failure (ADHF).

Main Methods:

  • The study enrolled 164 patients with ADHF: 129 with heart failure with reduced ejection fraction (HFrEF) and 35 with heart failure with preserved ejection fraction (HFpEF).
  • Blood levels of IL-6, soluble IL-6 receptor (sIL-6R), soluble gp130 (sgp130), and high-sensitivity C-reactive protein (hsCRP) were measured.
  • Correlations between these markers were analyzed in HFrEF and HFpEF groups.

Main Results:

  • HFpEF patients exhibited lower IL-6 and hsCRP levels but higher sIL-6R levels compared to HFrEF patients.
  • Significant positive correlations between IL-6 and hsCRP, IL-6 and sIL-6R, and IL-6 and sgp130 were observed in HFrEF.
  • In HFpEF, a stronger correlation was found only between IL-6 and hsCRP.

Conclusions:

  • Classical and trans-signaling pathways of IL-6 are differentially expressed in HFrEF and HFpEF during ADHF.
  • These findings enhance understanding of inflammation's role in CHF pathogenesis.
  • The results may inform the development of novel therapeutic strategies for CHF.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
577